TY - JOUR
TI - Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network
AU - Chiang, C.-Y.
AU - Ellwood, P.
AU - Ellwood, E.
AU - García-Marcos, L.
AU - Masekela, R.
AU - Asher, I.
AU - Badellino, H.
AU - Sanz, A.B.
AU - Douros, K.
AU - El Sony, A.
AU - Diaz, C.G.
AU - Rodríguez, M.S.A.
AU - Moreno-Salvador, A.
AU - Pérez-Martini, L.F.
AU - Filho, N.
AU - Shpakou, A.
AU - Sulaimanov, S.
AU - Tavakol, M.
AU - Valverde-Molina, J.
AU - Yousef, A.A.
AU - Pearce, N.
AU - The GAN COVID Study Group
JO - Pediatric Allergy and Immunology
PY - 2022
VL - 33
TODO - 1
SP - null
PB - John Wiley and Sons Inc
SN - 0905-6157, 1399-3038
TODO - 10.1111/pai.13709
TODO - corticosteroid, asthma;  child;  human;  pandemic, Adrenal Cortex Hormones;  Asthma;  Child;  COVID-19;  Humans;  Pandemics;  SARS-CoV-2
TODO - Background: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest. Methods: The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021. Results: Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3–16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23–12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02–5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization. Conclusions: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
ER -